Literature DB >> 1164818

Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion.

N L Benowitz, R T Jones.   

Abstract

In contrast to the tachycardia and unchanged or increased blood pressure seen after single doses, prolonged delta-9-tetrahydrocannabinol (THC) ingestion produced significant heart rate slowing and blood pressure lowering in hospitalized volunteers. Impaired circulatory responses to standing, exercise, Valsalva maneuver, and cold pressor testing suggest a state of sympathetic insufficiency. Marked weight gain was observed in all subjects, which has been shown to be related to fluid retention and plasma volume expansion. Tolerance developed to orthostatic hypotension, possibly related to plasma volume expansion, but did not develop to the supine hypotensive effects. Nearly complete tolerance developed to the tachycardia and psychological effects produced by smoked marijuana while ingesting THC. Electrocardiographic changes were minimal despite the large cumulative dose of THC. The hypothesis that THC has a biphasic effect on the sympathetic nervous system in man, producing excitation with single doses and inhibition with prolonged administration, is discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1164818     DOI: 10.1002/cpt1975183287

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  34 in total

1.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

2.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

Review 3.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

Review 4.  Toward drugs derived from cannabis.

Authors:  R Mechoulam; E A Carlini
Journal:  Naturwissenschaften       Date:  1978-04

Review 5.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetised rats.

Authors:  James R Padley; Qun Li; Paul M Pilowsky; Ann K Goodchild
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

7.  An abstinence syndrome following chronic administration of delta-9-terahydrocannabinol in rhesus monkeys.

Authors:  A B Fredericks; N L Benowitz
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

8.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

9.  Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension.

Authors:  Sándor Bátkai; Pál Pacher; Douglas Osei-Hyiaman; Svetlana Radaeva; Jie Liu; Judith Harvey-White; László Offertáler; Ken Mackie; M Audrey Rudd; Richard D Bukoski; George Kunos
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

10.  Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.

Authors:  Christopher T Dibble; Eli V Gelfand; Christopher P Cannon
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.